CD19-UCART not checked

Bioray Laboratories

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.”In the company’s words, NCT05381181 on ClinicalTrials.gov
Tested for
Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma
Main trialPhase 1
“The purpose of this study is to evaluate the safety and efficacy of Next-generation CD19-UCART in patients with relapsed or refractory B-cell hematological malignancies.”In the company’s words, NCT05381181 on ClinicalTrials.gov

Other drugs for Acute Lymphoblastic Leukemia

All 58 drugs for Acute Lymphoblastic Leukemia

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Unknown 30 May 2024 Safety and Efficacy Evaluation of Next-generation CD19-UCART
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow CD19-UCART

Following is part of Solo: you see every change to CD19-UCART the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in